PALO ALTO, Calif., Jan. 6 /PRNewswire/ -- Cell Biosciences, Inc., a
provider of nanoproteomic analysis systems to life science researchers, today
announced the placement of a next-generation protein analysis system
prototype, the Cell Biosciences CB1000, at the
The Cell Biosciences CB1000 prototype is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Because of the system's high detection sensitivity, cell signaling proteins can be measured reproducibly in as few as 25 cells. The CB1000 system will feature a significantly streamlined workflow, higher sample throughput, a much smaller footprint, and a host of performance improvements relative to previous systems. The CB1000 is scheduled for commercial release in mid-2009.
"The current Cell Biosciences platform is used heavily by multiple users at HIMC," said Dr. Hirschberg. "We are pleased to see the rapid advancement of Cell Biosciences' technology, and look forward to working with the new prototype system."
"To produce world-class instrumentation systems, it is critical to work
closely with world-class researchers," explained Bob Gavin, Vice President of
Engineering at Cell Biosciences. "Input from the
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems and assays for the measurement of phosphoprotein signaling and activation in extremely small biological samples. Our company's lead product is a capillary-based nanofluidic immunoassay platform that provides quantitative and reproducible data on key signaling pathways in precious biological samples, such as small tumor biopsies and stem cells. Cell Biosciences is located in Palo Alto, California.
|SOURCE Cell Biosciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved